Primary hypertension and nephropathy

被引:36
作者
Rosario, RF
Wesson, DE
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Dept Phys, Lubbock, TX 79430 USA
关键词
cardiovascular disease; chronic kidney disease; primary hypertension;
D O I
10.1097/01.mnh.0000214771.88737.ee
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Purpose of review The relationship between primary hypertension (formerly called essential hypertension) and hypertension-associated chronic kidney disease is complex and poorly understood. The strong association between hypertension-associated chronic kidney disease and cardiovascular disease supports the existence of common mediators. We will review data indicating common mediating mechanisms for cardiovascular disease and chronic kidney disease in primary hypertension. Recent findings Chronic kidney disease develops in primary hypertension due to local and systemic inflammatory mediators that cause endothelial injury. This injury is an important early step in the development of hypertension-associated vasculopathy that causes nephron ischemia with nephrosclerosis. Similar mechanisms mediate endothelial injury in cardiovascular disease and its progression. Subjects with primary hypertension at increased risk for chronic kidney disease are at higher risk for cardiovascular disease, the major cause of mortality in primary hypertension. Summary Primary hypertension is a modifiable risk factor for both cardiovascular disease and chronic kidney disease. Better understanding of how primary hypertension leads to these outcomes might help in the development of pharmacologic strategies that retard and/or prevent chronic kidney disease in primary hypertension. Because of the strong association between cardiovascular disease and chronic kidney disease in primary hypertension, this improved understanding will likely lead to better therapies to hinder the development and/or progression of cardiovascular disease, in addition to its benefits in preventing hypertension-associated chronic kidney disease.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 39 条
[1]
*3 NAT HLTH NUTR E, 2003, AM J KIDNEY DIS S, V41, pS29
[2]
BAKRIS GL, 2005, J AM SOC NEPHROL, V4, P75
[3]
BRENNER BM, 2004, BRENNER RECTORS KIDN, P2038
[4]
BRENNER BM, 2004, BRENNER RECTORS KIDN, P2124
[5]
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[6]
THE RENAL MEDULLA AND HYPERTENSION [J].
COWLEY, AW ;
MATTSON, DL ;
LU, SH ;
ROMAN, RJ .
HYPERTENSION, 1995, 25 (04) :663-673
[7]
THE STATUS OF PAI-1 AS A RISK FACTOR FOR ARTERIAL AND THROMBOTIC DISEASE - A REVIEW [J].
DAWSON, S ;
HENNEY, A .
ATHEROSCLEROSIS, 1992, 95 (2-3) :105-117
[8]
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy [J].
de Zeeuw, D ;
Remuzzi, G ;
Parving, HH ;
Keane, WF ;
Zhang, ZX ;
Shahinfar, S ;
Snapinn, S ;
Cooper, ME ;
Mitch, WE ;
Brenner, BM .
CIRCULATION, 2004, 110 (08) :921-927
[9]
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells [J].
Devaraj, S ;
Xu, DY ;
Jialal, I .
CIRCULATION, 2003, 107 (03) :398-404
[10]
Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins [J].
Engström, G ;
Janzon, L ;
Berglund, G ;
Lind, P ;
Stavenow, L ;
Hedblad, B ;
Lindgärde, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (12) :2054-2058